Investigational drug · Phase 2
SPN-817
Also called: BIS-001ER, Huperzine A
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Focal Onset Seizures, Focal Impaired Awareness Seizures, Epilepsy.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "SPN-817"
First trial start
2018
Apr 10, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SPN-817", any sponsor or status.
Conditions studied
As listed on its trial records.
- Focal Onset Seizures
- Focal Impaired Awareness Seizures
- Epilepsy
- Seizures, Epileptic
Approved drugs for the same conditions: Epilepsy and seizures · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "SPN-817" as an intervention, largest first.
- RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresPivotal-lookingRecruiting
Supernus Pharmaceuticals, Inc.Industry
NCT06798896 · 216 participants (planned) · Start Dec 30, 2024 · Primary completion Aug 2027
Drug: SPN-817; Placebo · For: Focal Onset Seizures
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 63 sites in all
- SPN-817 Open-Label Extension Study in Adults With Focal Onset SeizuresEnrolling by invitation
Supernus Pharmaceuticals, Inc.Industry
NCT07141329 · 100 participants (planned) · Start Jul 30, 2025 · Primary completion Dec 31, 2027
Drug: SPN-817 · For: Focal Onset Seizures
Sites: Tucson, Arizona; West Hills, California; Kissimmee, Florida · 8 sites in all
- Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant EpilepsyRecruiting
Supernus Pharmaceuticals, Inc.Industry
NCT05518578 · 60 participants (planned) · Start Feb 7, 2023 · Primary completion Dec 31, 2027
Drug: SPN-817 · For: Epilepsy; Seizures, Epileptic
Sites: Jacksonville, Florida; Miami, Florida; Randwick, Australia · 10 sites in all
Supernus Pharmaceuticals, Inc.Industry
NCT05102552 · 30 participants · Start Oct 19, 2021 · Primary completion Mar 25, 2022
Drug: SPN-817, Treatment B; SPN-817, Treatment C and 1 more · For: Healthy Volunteer
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Mechanisms of traditional Chinese medicine-derived active components in the treatment of Alzheimer's disease: A comprehensive review.
Tian Y, Guo J, Lin X, et al. · J Ethnopharmacol 2027
- Molecular Insights on the Reduction-Dependent Electronic Modulation of Graphene Oxide Surface Toward Reactivity and Acetylcholinesterase Inhibition of Alzheimer's Drugs.
Phanrang PT, Upadhyaya J, Chandra AK, et al. · Chemphyschem 2026
- Research Trends and Mechanistic Insights Into Natural Medicines for Alzheimer's Disease: A Bibliometric Analysis and Narrative Review.
Wang M, Zhang X, Yang H, et al. · Phytother Res 2026
- Huperzine A Attenuates Oxidative Stress-Induced H9c2 Cardiomyoblast Injury Through AKT-Associated Survival Signaling.
Zhang Y, Long H, Qiao L, et al. · Antioxidants (Basel) 2026
- Probing Acetylcholinesterase Activity and Enzyme Inhibitor Evaluation by Electrostatic-Gating Nanopores.
Li L, Li S, Zhang Y, et al. · Anal Chem 2026
- Light spectrum effects on huperzine A and B accumulation in axenic gametophyte cultures of Huperzia selago (L.) Bernh. ex Schrank et Mart.
Szypua WJ, Maciejczyk M, Wileska B · Front Plant Sci 2026
Also in development for Focal Onset Seizures
- AzetukalnerXEN1101Phase 39 trials
Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder
- RAP-219Phase 35 trials
Rapport Therapeutics Inc. · Focal Epilepsy, Epilepsy, Focal Seizure
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.